Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
DEXMEDETOMIDINE-TEVA, TEVA-DEXMEDETOMIDINE (Teva Pharma Australia Pty Ltd)
Product name
DEXMEDETOMIDINE-TEVA, TEVA-DEXMEDETOMIDINE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
161 working days (255)
Active ingredients
dexmedetomidine hydrochloride
Registration type
New generic medicine
Indication
DEXMEDETOMIDINE-TEVA, TEVA-DEXMEDETOMIDINE (injection) is indicated for:
ICU Sedation
- For sedation of initially intubated patients during treatment in an intensive care setting.
Procedural Sedation
- For sedation of non-intubated patients prior to and/or during surgical and other procedures.